|
|
 |
|
Viewing report
|
|
|
|
Emerging Generic Drug Companies Worldwide 2007
Espicom Business Intelligence Ltd, Feb 2007, Pages: 364
The operating environment for medium-sized generic drug manufacturers is changing rapidly as the industry matures and growth focuses on new market opportunities.
Consolidation continues to affect companies, as acquisition becomes the instrument of choice in the drive for market share.
But…
-Who are the medium-sized companies of note?
-How well do they perform?
-What products do they produce?
-Where are they located?
This report will tell you!
Who’s next? The rapidly changing face of the global generics industry…
The pace of corporate consolidation grows ever faster - eight significant acquisitions were announced in 2006:
Andrx/ Watson
Mayne Pharma/ Hospira
Betapharm/ Dr Reddy's
Pliva/ Barr Pharmaceutical
Matrix/ Mylan Labs
Zentiva/sanofi-aventis
Terapia/ Ranbaxy
Hemofarm/ Stada Arzneimittel
Sindan/Actavis
Increasingly the industry is being rationalised and dominated by fewer and fewer large players. Teva and Sandoz may be fighting it out for the top spot but the speed of change is seeing the corporate landscape change continuously.
And what about 2007?
All generic companies are operating in increasingly crowded and competitive environments as far as the traditional high value markets such as the UK and USA are concerned. Focus is switching to growth markets such as France, Spain, Brazil and Italy where significant double-digit growth is forecast to 2011. With business cycles growing shorter and shorter, market entry is quicker and more reliable through acquisition and partnering.
Drivers for change
In addition to ongoing expansion, there are other drivers which are causing the generic companies to consider the future:
-The number of new generic drug opportunities are reducing in line with the decline in NDAs over recent years. Furthermore, the branded industry is far more aware of the potential to protect revenues by issuing early branded generics and/or new formulations.
-The increasing introduction of biotech based products will present regulatory and production hurdles to generic manufacturers in the future.
Identify new business opportunities and assess risk
For everyone needing to evaluate the generic industry’s competitive landscape this new, thoroughly researched 350-page report Emerging Generic Drug Companies Worldwide 2007 (Published February 2007) is essential reading.
For each company where available or appropriate:
BACKGROUND
A summary of the company’s foundation and main business interests
PRODUCT RANGE
Details of ANDAs approved or products represented
FINANCIAL
Financial performance or funding data
STRATEGIC ALLIANCES
Details of significant marketing and supply agreements
CONTACT INFORMATION
Use this report to…
-Identify commercial partners
-Understand the developing generic industry in key markets worldwide
-Profile the competitive environment in the increasingly important medium sized company sector
-Seek out companies manufacturing/marketing similar product lines
-Assess the investment potential of these developing companies
Customers who bought this item also bought
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
Injectable Generic Drugs: Prospects and Opportunities to 2010
Sawai Pharmaceuticals Generics Company Intelligence Report
World Generic Drug Markets: Competitive Benchmarking
The Latin American Market for Generic Drugs - A Comparative Study of 7 Key Markets
The Worldwide Prescription Drug Market 2004
Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies
Emerging Antiviral Drug Targets
|
|
|
|
